StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)

Close on Nov 17, 2026Market cap $110.85MP/E –Yield –

Atrium Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Atrium Therapeutics's enterprise value was -$127.74M on Nov 11, 2026.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$127.74M–

More Atrium Therapeutics figures

See a number that looks wrong?